Research Summary

Dr. Mi-Ok Kim has joined the HDFCCC as Director of the Biostatistics Core. The Core is responsible for providing support for protocol development, review and analysis for clinical studies, and statistical expertise for research collaborations with Cancer Center investigators in all disciplines across the spectrum of basic, clinical and population sciences. Dr. Kim will lead the Core and work directly with Cancer Center leadership on developing and implementing a strategic and integrated shared resource plan.

Dr. Kim joins us from Cincinnati Children’s Hospital Medical Center in Cincinnati, OH, where she directed the Biostatistics Unit for the Cancer and Blood Diseases Institute. Notable collaborations included Children's Tumor Foundation’s Neurofibromatosis (NF) Therapeutic Consortium that builds up a preclinical pipeline for screening candidate drug therapies in animal model systems. Dr. Kim also developed a research program in novel clinical trial designs that incorporate biomarker information and aim to optimize patient benefits. With the expertise in the trial design she served on the faculty for the American Association for Cancer Research (AACR) sponsored 2015 Methods in Cancer Biostatistics Workshop.

Dr. Kim will also join the Department of Epidemiology and Biostatistics as Professor of Biostatistics, continuing academic contributions to the field of biostatistics and providing biostatistical support broadly on campus. Trained as a mathematical statistician, Dr. Kim is an independent statistical method researcher with research interest in non- and semi-parametric statistics, and longitudinal and survival data analysis. She has been supported by NIH and National Science Foundation (NSF) awards, and published in prestigious journals such as the Annals of Statistics and the Journal of the American Statistical Association. Her recent research focuses on causal inference using structured data for comparative effectiveness research (CER) and patient-centered outcome research (PCOR). Registries, network databases and Electronic Health Record (EHR) often impose a hierarchical structure where subjects or patients are clustered, for example, by geographical area of residence, health care provider or health plan. The data structure is often associated with unmeasured characteristics of individuals or health care providers. Supported by the Patient-Centered Outcome Research Institute (PCORI), Dr. Kim and her research team study optimal handling of the complex data structure both in the treatment selection decision process and the outcome analysis in order to minimize bias and maximize efficiency of the causal inference. Application studies of the project include pediatric Crohn’s disease (CD) and kidney transplant study.

Research Funding

  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant, Biostatistics Core Director. Sponsor: NIH/NCI, Sponsor Award ID: P30 CA082103
  • July 1, 2008 - December 31, 2018 - Risk Stratification & Identification of immunogenic and microbial markers of rapid disease progression in children with Crohn’s disease, Biostatistics Core Director. Sponsor: CCFA, Sponsor Award ID: Research Initiative Grant
  • January 1, 2015 - June 30, 2018 - Propensity Score-based Methods for CER Using Multilevel Data: What Works Best When, PI. Sponsor: PCORI, Sponsor Award ID: ME-1403-13922
  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant, Biostatistics Core Director. Sponsor: NIH/NCI, Sponsor Award ID: P30 CA082103

Education

MS: Statistics, University of Illinois, Urbana-Champaign, IL, 2000
PhD: Statistics, University of Illinois, Urbana-Champaign, IL, 2003

Honors & Awards

  • 1997
    Fellowship,University of Illinois at Urbana-Champaign
  • 2001
    First Prize,Capital One Financial Data Challenge Competition
  • 2002
    Norton Prize, Robert Bohrer Workshop for Student Papers in Statistics, University of Illinois at Urbana-Champaign
  • 2004
    Junior Faculty Travel Award,International Conference on Robust Statistics (ICORS)
  • 2008
    Travel Award, American Association for Cancer Research (AACR) Cancer Biostatistics Workshop

Selected Publications

  1. Bhola NE, Njatcha C, Hu L, Lee ED, Shiah JV, Kim MO, Johnson DE, Grandis JR. PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head Neck. 2021 Aug 03.  View on PubMed
  2. Kolodzie K, Cakmakkaya OS, Boparai ES, Tavakol M, Feiner JR, Kim MO, Newman TB, Niemann CU. Perioperative Normal Saline Administration and Delayed Graft Function in Patients Undergoing Kidney Transplantation: A Retrospective Cohort Study. Anesthesiology. 2021 Jul 15.  View on PubMed
  3. Sheng Y, Sun Y, Huang CY, Kim MO. Synthesizing external aggregated information in the penalized Cox regression under population heterogeneity. Stat Med. 2021 Jun 16.  View on PubMed
  4. Sheng Y, Sun Y, Huang CY, Kim MO. Synthesizing external aggregated information in the presence of population heterogeneity: A penalized empirical likelihood approach. Biometrics. 2021 Feb 02.  View on PubMed
  5. He Y, Kim S, Kim MO, Saber W, Ahn KW. Optimal treatment regimes for competing risk data using doubly robust outcome weighted learning with bi-level variable selection. Comput Stat Data Anal. 2021 Jun; 158.  View on PubMed
  6. Na Y, Hall A, Choi K, Hu L, Rose J, Coover RA, Miller A, Hennigan RF, Dombi E, Kim MO, Subramanian S, Ratner N, Wu J. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene. 2021 02; 40(5):951-963.  View on PubMed
  7. Harun N, Liu C, Kim MO. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control. Pharm Stat. 2020 09; 19(5):613-625.  View on PubMed
  8. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. J Surg Oncol. 2019 Dec 11.  View on PubMed
  9. Krishnakumar C, Ballengee CR, Liu C, Kim MO, Baker SS, Baldassano RN, Cohen SA, Crandall WV, Denson LA, Dubinsky MC, Evans J, Gokhale R, Griffiths A, Guthery SL, Oliva-Hemker M, Heyman MB, Keljo D, Kellermayer R, Leleiko NS, Mack DR, Markowitz JF, Moulton DE, Noe JD, Otley AR, Patel AS, Pfefferkorn M, Rabizadeh S, Rosh JR, Snapper S, Walters TD, Ziring D, Mondal K, Kappelman MD, Hyams JS, Kugathasan S. Variation in Care in the Management of Children With Crohn's Disease: Data From a Multicenter Inception Cohort Study. Inflamm Bowel Dis. 2019 06 18; 25(7):1208-1217.  View on PubMed
  10. Liu SY, Liu C, Nehus E, Macaluso M, Lu B, Kim MO. Propensity score analysis for correlated subgroup effects. Stat Methods Med Res. 2020 04; 29(4):1067-1080.  View on PubMed
  11. Hall A, Choi K, Liu W, Rose J, Zhao C, Yu Y, Na Y, Cai Y, Coover RA, Lin Y, Dombi E, Kim M, Levanon D, Groner Y, Boscolo E, Pan D, Liu PP, Lu QR, Ratner N, Huang G, Wu J. RUNX represses Pmp22 to drive neurofibromagenesis. Sci Adv. 2019 04; 5(4):eaau8389.  View on PubMed
  12. Fletcher JS, Wu J, Jessen WJ, Pundavela J, Miller JA, Dombi E, Kim MO, Rizvi TA, Chetal K, Salomonis N, Ratner N. Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI Insight. 2019 Feb 07; 4(3).  View on PubMed
  13. Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. J Exp Med. 2019 02 04; 216(2):419-427.  View on PubMed
  14. Haberman Y, Schirmer M, Dexheimer PJ, Karns R, Braun T, Kim MO, Walters TD, Baldassano RN, Noe JD, Rosh J, Markowitz J, Crandall WV, Mack DR, Griffiths AM, Heyman MB, Baker SS, Kellermayer R, Moulton D, Patel AS, Gulati AS, Steiner SJ, LeLeiko N, Otley A, Oliva-Hemker M, Ziring D, Kirschner BS, Keljo DJ, Guthery SL, Cohen SA, Snapper S, Evans J, Dubinsky M, Aronow B, Hyams JS, Kugathasan S, Huttenhower C, Xavier RJ, Denson LA. Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosis. Mucosal Immunol. 2019 03; 12(2):491-502.  View on PubMed
  15. Fletcher JS, Springer MG, Choi K, Jousma E, Rizvi TA, Dombi E, Kim MO, Wu J, Ratner N. STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma. Oncogene. 2019 04; 38(15):2876-2884.  View on PubMed
  16. Kim MO, Zhou M. COMPARISON OF EXTENDED EMPIRICAL LIKELIHOOD METHODS: SIZE AND SHAPE OF TEST BASED CONFIDENCE REGIONS. Statistica Sinica. 2018; (29):371-386.  View on PubMed
  17. Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG, Liu HY, Spillinger A, Shah AT, Tanasa B, Straessler K, Hazard FK, Spunt SL, Marina N, Kim GE, Cho SJ, Avedian RS, Mohler DG, Kim MO, DuBois SG, Hawkins DS, Sweet-Cordero EA. Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov. 2019 01; 9(1):46-63.  View on PubMed
  18. Kim HJ, Lu B, Nehus EJ, Kim MO. Estimating heterogeneous treatment effects for latent subgroups in observational studies. Stat Med. 2019 02 10; 38(3):339-353.  View on PubMed
  19. Chandradevan R, Hofmekler T, Mondal K, Harun N, Venkateswaran S, Somineni HK, Ballengee CR, Kim MO, Griffiths A, Noe JD, Crandall WV, Snapper S, Rabizadeh S, Rosh JR, Walters TD, Bertha M, Dubinsky MC, Denson LA, Sauer CG, Markowitz JF, LeLeiko NS, Hyams JS, Kugathasan S. Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles. Inflamm Bowel Dis. 2018 09 15; 24(10):2285-2290.  View on PubMed
  20. Ballengee CR, Stidham RW, Liu C, Kim MO, Prince J, Mondal K, Baldassano R, Dubinsky M, Markowitz J, Leleiko N, Hyams J, Denson L, Kugathasan S. Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 08; 17(9):1799-1806.  View on PubMed

Go to UCSF Profiles, powered by CTSI